Skip to main content

Joaquin Burgos Cibrian

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

Joaquin Burgos Cibrian

Institutions of which they are part

Main researcher
Infectious Diseases
Vall Hebron Institut de Recerca

Projects

Incorporació del candidat a l'àrea de Malalties Infeccioses

IP: Benito Almirante Gragera
Collaborators: Joaquin Burgos Cibrian, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 135000
Reference: JR15/00015
Duration: 01/01/2016 - 31/12/2018

Malalties Infeccioses (GRC)

IP: Benito Almirante Gragera
Collaborators: Adria Curran Fàbregas, Oscar Len Abad, Manuel Crespo Casal, Inmaculada Ocaña Rivera, Nuria Fernández Hidalgo, Joan Gavaldà Santapau, Esteve Ribera Pascuet, Ma Dolores Rodríguez Pardo, Israel Molina Romero, Fernando M Salvador Velez, Carles Pigrau Serrallach, Isabel Ruiz Camps, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, Adrián Sánchez Montalvá
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding:
Reference: 2014 SGR 759
Duration: 01/01/2014 - 31/12/2016

Malalties infeccioses

IP: Albert Pahissa Berga
Collaborators: Joaquin Burgos Cibrian, Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 72000
Reference: CM12/00207
Duration: 01/01/2013 - 31/12/2014

Red de SIDA-RIS

IP: Esteve Ribera Pascuet
Collaborators: Adria Curran Fàbregas, Vicenç Falcó Ferrer, Manuel Crespo Casal, Inmaculada Ocaña Rivera, Estrella Caballero Requero, Pere Soler Palacín, Maria Espiau Guarner, María José Buzón Gómez, Jordi Navarro Mercadé, Joaquin Burgos Cibrian, Judit Grau Exposito, Andrea Martín Nalda, Marie Antoinette Frick
Funding agency: Instituto de Salud Carlos III
Funding: 200800
Reference: RD12/0017/0003
Duration: 01/01/2013 - 30/09/2017

Related news

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

The initiative, carried out at the Consulate of Bolivia, has resulted in 307 new tests for the diagnosis of Chagas disease

The study shows that blocking the KLRG1 receptor helps to recover the activity of the natural killer cells of the immune system and reactivate the virus reservoir to fight infection.

Related professionals

Neus Bellera Gotarda

Neus Bellera Gotarda

Cardiovascular Diseases
Read more
Marta Esteve  Costal

Marta Esteve Costal

Administrative
Tenders and Procurement Unit
Finances Area
Read more
Mónica Fernández Cancio

Mónica Fernández Cancio

Senior researcher
Growth and Development
Read more
Vanesa Félix Brenes

Vanesa Félix Brenes

Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.